Pharmacodynamics of atabecestat (JNJ-54861911), an oral BACE1 inhibitor in patients with early Alzhe...
Pharmacodynamics of atabecestat (JNJ-54861911), an oral BACE1 inhibitor in patients with early Alzheimer's disease: randomized, double-blind, placebo-controlled study
About this item
Full title
Author / Creator
Timmers, Maarten , Streffer, Johannes Rolf , Russu, Alberto , Tominaga, Yushin , Shimizu, Hiroko , Shiraishi, Ayako , Tatikola, Kanaka , Smekens, Pascale , Börjesson-Hanson, Anne , Andreasen, Niels , Matias-Guiu, Jorge , Baquero, Miquel , Boada, Mercè , Tesseur, Ina , Tritsmans, Luc , Van Nueten, Luc and Engelborghs, Sebastiaan
Publisher
England: BioMed Central Ltd
Journal title
Language
English
Formats
Publication information
Publisher
England: BioMed Central Ltd
Subjects
More information
Scope and Contents
Contents
β-Secretase enzyme (BACE) inhibition has been proposed as a priority treatment mechanism for Alzheimer's disease (AD), but treatment initiation may need to be very early. We present proof of mechanism of atabecestat (also known as JNJ-54861911), an oral BACE inhibitor for the treatment of AD, in Caucasian and Japanese populations with early AD who...
Alternative Titles
Full title
Pharmacodynamics of atabecestat (JNJ-54861911), an oral BACE1 inhibitor in patients with early Alzheimer's disease: randomized, double-blind, placebo-controlled study
Authors, Artists and Contributors
Author / Creator
Identifiers
Primary Identifiers
Record Identifier
TN_cdi_doaj_primary_oai_doaj_org_article_29adc1da679f4c53b4ec494c0c1dcf5e
Permalink
https://devfeature-collection.sl.nsw.gov.au/record/TN_cdi_doaj_primary_oai_doaj_org_article_29adc1da679f4c53b4ec494c0c1dcf5e
Other Identifiers
ISSN
1758-9193
E-ISSN
1758-9193
DOI
10.1186/s13195-018-0415-6
